William T. Barry

15.9k citations

191 papers · 8.4k indexed · 3 hit papers · h-index 47

Impact in

Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy

Papers in

Cancer Research 65
- Breast Cancer Treatment Studies 46
- Cancer Genomics and Diagnostics 17
Oncology 105
- HER2/EGFR in Cancer Research 36
- Cancer Treatment and Pharmacology 28

Co-authors: Eric P. Winer Ian E. Krop Sara M. Tolaney Fred A. Wright Romualdo Barroso‐Sousa F. Stephen Hodi Ana C. Garrido-Castro Andrew B. Nobel
Journals: Journal of Clinical Oncology (49 papers)Breast Cancer Research and Treatment (12 papers)Cancer Research (10 papers)Clinical Cancer Research (7 papers)Annals of Surgical Oncology (7 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

William T. Barry

190 papers receiving 8.3k citations

Hit Papers

align trajectories log scale

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens 2017 · 768 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 JAMA Oncology
2015 New England Journal of Medicine
2014 The Lancet Oncology

Peers

Countries citing papers authored by William T. Barry

Since Specialization

Citations

This map shows the geographic impact of William T. Barry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William T. Barry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William T. Barry more than expected).

Fields of papers citing papers by William T. Barry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William T. Barry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William T. Barry. The network helps show where William T. Barry may publish in the future.

Co-authors

The 25 scholars most cited alongside William T. Barry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William T. Barry Line = papers co-authored together William T. Barry links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study Cancer ·Jennifer A. Ligibel, Yue Zheng, William T. Barry, Tal Sella, Kathryn J. Ruddy, Mary L. Greaney, Shoshana M. Rosenberg, Karen M. Emmons, Ann H. Partridge	2023	1
2	Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity JACC Heart Failure ·Shom Goel, Jia Liu, Hao Guo, William T. Barry, Richard H. Bell, Bronwyn Murray, Jodi Lynch, Patricia Bastick, Lorraine A. Chantrill, Belinda E. Kiely, Ehtesham Abdi, Josie Rutovitz, Ray Asghari, Anne Sullivan, Michelle Harrison, Maija R.J. Kohonen‐Corish, Jane Beith	2019	30
3	Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers Cancer ·Yun Song, William T. Barry, Davinia Seah, Nadine Tung, Judy E. Garber, Nancy U. Lin	2019	78
4	Breast cancer‐specific survival by age: Worse outcomes for the oldest patients Cancer ·Rachel A. Freedman, Nancy L. Keating, Nancy U. Lin, Eric P. Winer, Inês Vaz-Luís, Joyce Lii, Pedro Exman, William T. Barry	2018	55
5	Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis European Journal of Cancer ·Carmen Criscitiello, Mehra Golshan, William T. Barry, Giulia Viale, Stephanie M. Wong, Michele Santangelo, Giuseppe Curigliano	2018	30
6	Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance) Clinical Cancer Research ·Mark Jesus M. Magbanua, Hope S. Rugo, Denise M. Wolf, Louai Hauranieh, Ritu Roy, Praveen Pendyala, Eduardo V. Sosa, Janet H. Scott, Jin Sun Lee, Brandelyn N. Pitcher, Terry Hyslop, William T. Barry, Steven J. Isakoff, Maura N. Dickler, Laura van’t Veer, John W. Park	2018	36
7	The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women Cancer Research ·Sung Jin Huh, Hannah Oh, Michael Peterson, Vanessa Almendro, Rong Hu, Michaela Bowden, Rosina L. Lis, Maura B. Cotter, Massimo Loda, William T. Barry, Kornélia Polyák, Rulla M. Tamimi	2016	41
8	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer Clinical Cancer Research ·Rinath Jeselsohn, William T. Barry, Ilenia Migliaccio, Chiara Biagioni, Jin Zhao, Jonas de Tribolet-Hardy, Cristina Guarducci, Martina Bonechi, Naomi Laing, Eric P. Winer, Myles Brown, Angelo Di Leo, Luca Malorni	2016	20
9	Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis Breast Cancer Research and Treatment ·Antonio Di Meglio, Rachel A. Freedman, Nancy U. Lin, William T. Barry, Otto Metzger, Nancy L. Keating, Tari A. King, Mario Roberto Sertoli, Francesco Boccardo, Eric P. Winer, Inês Vaz-Luís	2016	31
10	MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy Cancer Discovery ·Manish Neupane, Allison Clark, Serena Landini, Nicolai J. Birkbak, Aron C. Eklund, Elgene Lim, Aedín C. Culhane, William T. Barry, Steven E. Schumacher, Rameen Beroukhim, Zoltán Szállási, Marc Vidal, David E. Hill, Daniel P. Silver	2015	49
11	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib Journal of Clinical Oncology ·Lisa A. Carey, Donald A. Berry, Constance Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay N. Harris, David W. Ollila, Ian E. Krop, N. Lynn Henry, Douglas Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael D. Iglesia, Maggie C.U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis	2015	263
12	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study The Lancet Oncology ·Joyce F. Liu, William T. Barry, Michael J. Birrer, Jung Min Lee, Ronald J. Buckanovich, Gini F. Fleming, B.J. Rimel, Mary K. Buss, Sreenivasa Nattam, Jean Hurteau, Weixiu Luo, Philippa Quy, Christin Whalen, Lisa Obermayer, Hang Lee, Eric P. Winer, Elise C. Kohn, S. Percy Ivy, Ursula A. Matulonis Hit paper breakdown →	2014	446
13	A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer Clinical Cancer Research ·Angeles Alvarez Secord, Deanna Teoh, William T. Barry, Miao Yu, Gloria Broadwater, Laura J. Havrilesky, Paula S. Lee, Andrew Berchuck, Johnathan M. Lancaster, Robert M. Wenham	2012	50
14	Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer Molecular Cancer Therapeutics ·Mickey K. Kim, Takuya Osada, William T. Barry, Xiao Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, Bryan M. Clary, Timothy Clay, Michael A. Morse, Philip G. Febbo, H. Kim Lyerly, David S. Hsu	2012	31
15	Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle BMC Medical Genomics ·Eric B. Meltzer, William T. Barry, Thomas A. D’Amico, Robert D. Davis, Shu S. Lin, Mark W. Onaitis, Lake Morrison, Thomas A. Sporn, Mark P. Steele, Paul W. Noble	2011	86
16	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity Clinical Cancer Research ·Zachary C. Hartman, Jun-Ping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, Dong‐Wan Kim, Wenle Xia, Neil L. Spector, Jeffrey R. Marks, William T. Barry, Amy Hobeika, Gayathri R. Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, Timothy M. Clay	2010	21
17	The Oncotype DX Recurrence Score Is Correlated With a Composite Index Including Routinely Reported Pathobiologic Features Cancer Investigation ·Joseph Geradts, Sarah M. Bean, Rex C. Bentley, William T. Barry	2010	43
18	Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome Journal of Clinical Oncology ·William T. Barry, Dawn Kernagis, Holly K. Dressman, Ryan J. Griffis, J'Vonne D. Hunter, John A. Olson, Jeff Marks, Geoffrey S. Ginsburg, P. Kelly Marcom, Joseph R. Nevins, Joseph Geradts, Michael Datto	2010	84
19	A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia Clinical Cancer Research ·Daphne R. Friedman, J. Brice Weinberg, William T. Barry, Barbara K. Goodman, Alicia D. Volkheimer, Karen M. Bond, Youwei Chen, Ning Jiang, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Carlos M. DeCastro, Anil Potti, Joseph R. Nevins	2009	28
20	Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo International Journal of Cancer ·Michael A. Morse, Jun-Ping Wei, Zachary C. Hartman, Wenle Xia, Xiaosong Ren, Gangjun Lei, William T. Barry, Takuya Osada, Amy Hobeika, Sharon Peplinski, Haixiang Jiang, Gayathri R. Devi, Wei Chen, Neil L. Spector, Andrea Amalfitano, H. Kim Lyerly, Timothy M. Clay	2009	19

About William T. Barry

William T. Barry is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine and Geriatrics and Gerontology, having authored 191 papers that have together received 8.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (46 papers), HER2/EGFR in Cancer Research (36 papers), Cancer Treatment and Pharmacology (28 papers), Advanced Breast Cancer Therapies (22 papers), Cancer Genomics and Diagnostics (17 papers), Lung Cancer Treatments and Mutations (17 papers), Gene expression and cancer classification (15 papers) and BRCA gene mutations in cancer (15 papers). The work is most often cited by research in Cancer Research (2.4k citations), Oncology (4.3k citations), Reproductive Medicine (616 citations), Geriatrics and Gerontology (274 citations) and Pulmonary and Respiratory Medicine (1.6k citations). William T. Barry has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Eric P. Winer, Ian E. Krop, Sara M. Tolaney, Fred A. Wright, Romualdo Barroso‐Sousa, F. Stephen Hodi, Ana C. Garrido-Castro, Andrew B. Nobel, Le Min and Mehra Golshan. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, Cancer Research, Clinical Cancer Research and Annals of Surgical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact